1. Special NIH Funding Opportunities
Elizabeth Wilder, Ph.D.
Director
Office of Strategic Coordination
Division of Program Coordination, Planning, and Strategic Initiatives
Office of the NIH Director
March 12, 2014

2. National Institute of Diabetes and Digestive and Kidney Diseases
27 NIH Institutes and Centers
National Institute of
Deafness and
Communications Disorders
Clinical Center
NIAMS
National Institute of Arthritis and
Musculoskeletal and Skin Diseases
National Institute of
Biomedical Imaging
and Bioengineering
International Center
National Institute of Diabetes and
Digestive and Kidney Diseases

3. The Office of the Director (OD)
The goals of the agency are as follows:
- foster fundamental creative discoveries, innovative research strategies, and their applications as a basis to advance significantly the Nation's capacity to protect and improve health;
- develop, maintain, and renew scientific human and physical resources that will ensure the Nation's capability to prevent disease;
- expand the knowledge base in medical and associated sciences in order to enhance the Nation's economic well-being and ensure a continued high return on the public investment in research; and
- exemplify and promote the highest level of scientific integrity, public accountability, and social responsibility in the conduct of science.
In realizing these goals, the NIH provides leadership and direction to programs designed to improve the health of the Nation by conducting and supporting research:
- in the causes, diagnosis, prevention, and cure of human diseases;
- in the processes of human growth and development;
- in the biological effects of environmental contaminants;
- in the understanding of mental, addictive and physical disorders; and
- in directing programs for the collection, dissemination, and exchange of information in medicine and health, including the development and support of medical libraries and the training of medical librarians and other health information specialists. 3

4. Current Common Fund Programs
Extracellular RNA
Communication
Undiagnosed
Diseases
Program
Strengthening
the
Biomedical Research
Workforce
Health
Economics
PROMIS:
Clinical
Outcomes
Assessment
Big Data to
Knowledge
(BD2K)
Single
Cell
Analysis
Regulatory
Science
NIH
Center for
Regenerative
Medicine
The 4D
Nucleome
Enhancing the Diversity
of the NIH-Funded
Workforce
Glycoscience
NIH Medical
Research
Scholars
Protein
Capture
Gulf Oil Spill
Long Term
Follow Up
NIH
Common Fund
Human
Microbiome
Nanomedicine
HCS Research
Collaboratory
High-Risk
Research
Knockout
Mouse
Phenotyping
Global
Health
Pioneer Awards
New Innovator Awards
Transformative Research Awards
Early Independence Awards
Illuminating the
Druggable Genome
Change colors
Structural
Biology
Building Blocks,
Biological Pathways
And Networks
Library of
Integrated Network-
Based Cellular
Signatures
(LINCS)
Science of
Behavior
Change
Metabolomics
Genotype-
Tissue
Expression
Epigenomics

5. Criteria for Common Fund Programs
Common Fund program areas are selected through a strategic planning process that identifies trans-NIH challenges or areas of exceptional opportunity that meet the following criteria:
Transformative: Must have potential for exceptionally high impact — to dramatically affect biomedical and/or behavioral research over the next decade
Synergistic: Outcomes must synergize with research supported by the NIH Institues and Centers (ICs) to promote and advance individual missions of ICs and to benefit health
Catalytic: Must achieve a defined set of goals within 5-10 years which will then catalyze further work supported by the ICs
Cross-Cutting: Program areas must cut across missions of multiple NIH ICs. Similarly, programs must be relevant to multiple diseases or conditions
Unique: Must be something no other entity is likely or able to do, or, if similar efforts exist, the Common Fund programs must be coordinated with others. The CF supports projects that would be unlikely to be supported through traditional, investigator-initiated mechanisms.
FY11 Budget: $543M

6. CF Programs Build “Foundations” to Catalyze Research
■ New Approaches to Foster Innovation and Invigorate the Research Workforce
■ High-Risk High-Reward (Pioneer, New Innovator, Transformative Research, Early Independence Awards)
■ Broadening Experiences in Scientific Training (BEST) Awards (New in FY13)
■ Enhancing Diversity in the NIH-funded Workforce (New in FY13)
■ New Tools, Infrastructure, and Data to Support or Establish New Fields of Study
■ Extracellular RNA Communication
■ Epigenomics
■ Knock-Out Mouse Phenotyping Project (KOMP2)
■ Illuminating the Druggable Genome (New in FY14)
■ New Technologies and Approaches to Overcome Barriers to Progress in a Field
■ Structural Biology
■ PROMIS: Patient Report Outcomes Management System
■ Microphysiological Systems for Drug Screening

7. High-Risk High-Reward (HRHR) Research
New approaches to support exceptionally creative scientists who propose highly innovative approaches to major contemporary challenges in biomedical research
Novel approaches to peer review and funding mechanisms
TRA
Preliminary data not required
Shortened application
Transformative Research Awards allow multi-disciplinary teams of investigators

8. High-Risk High-Reward (HRHR) Research Awards TRANSFORMATIVE RESEARCH
EARLY INDEPENDENCE
PIONEER
NEW INNOVATOR
Junior investigators (within 1 year of Ph.D. or medical residency)
Who?
All career stages, applications from teams of investigators welcome
All career stages
Early stage Investigators
Transformative ideas that may involve large budgets
Creative scientists proposing paradigm shifting research
Early stage investigators proposing high potential impact research
Junior scientists ready for research independence
What?
All areas of basic, clinical and translational science within the NIH mission
Budget?
Up to $25 million per year for 5 years
Up to $500,000 per year for 5 years
Up to $300,000 per year for 5 years
Up to $250,000 per year for 5 years
Prelim data?
Preliminary data requirements less stringent than R01 award
Preliminary data not required
Preliminary data not required
Preliminary data not required
For more information:

9. High-Risk High-Reward (HRHR) Research Awards TRANSFORMATIVE RESEARCH
We WILL have all 3
competitions again next year!
Look for announcements next spring.
TRANSFORMATIVE RESEARCH
We WILL have all 4
competitions again next year!
EARLY INDEPENDENCE
PIONEER
NEW INNOVATOR
Junior investigators (within 1 year of Ph.D. or medical residency)
Who?
All career stages, applications from teams of investigators welcome
All career stages
Early stage Investigators
Transformative ideas that may involve large budgets
Creative scientists proposing paradigm shifting research
Early stage investigators proposing high potential impact research
Junior scientists ready for research independence
What?
All areas of basic, clinical and translational science within the NIH mission
Budget?
Up to $25 million per year for 5 years
Up to $500,000 per year for 5 years
Up to $300,000 per year for 5 years
Up to $250,000 per year for 5 years
Prelim data?
Preliminary data requirements less stringent than R01 award
Preliminary data not required
Preliminary data not required
Preliminary data not required
For more information:

10. CF Programs Build “Foundations” to Catalyze Research
■ New Approaches to Foster Innovation and Invigorate the Research Workforce
■ High-Risk High-Reward (Pioneer, New Innovator, Transformative Research, Early Independence Awards)
■ Broadening Experiences in Scientific Training (BEST) Awards (New in FY13)
■ Increasing Diversity in the NIH-funded Workforce (New in FY13)
■ New Tools, Infrastructure, and Data to Support or Establish New Fields of Study
■ Extracellular RNA Communication
■ Epigenomics
■ Knock-Out Mouse Phenotyping Project (KOMP2)
■ Illuminating the Druggable Genome (New in FY14)
■ New Technologies and Approaches to Overcome Barriers to Progress in a Field
■ Structural Biology
■ PROMIS: Patient Report Outcomes Management System
■ Microphysiological Systems for Drug Screening

11. Extracellular RNA Communication
Trans-NIH Involvement:
-- Led by NCI and NCATS
-- Working Group Members from 18 Institutes/Centers

12. Epigenomics: Data and Resources for the Biomedical Research Community
Reference epigenome maps
Technology development
Discovery of novel marks
Epigenomic basis of disease
International coordination
Data sharing
Standards
For more information:

13. Knockout Mouse Phenotyping Program (KOMP2)
■ Partnership with International Mouse Phenotyping Consortium (IMPC)
■ Standardized, broad phenotyping of 5,000 KO mice derived from IKMC ES cells
■ Definition of in vivo function of mammalian genes and identification of new models of disease
■ Data stored in a centralized database (European Molecular Biology Lab)
Cohort breeding
Phenotyping
Data Upload
KOMP Repository
Mouse Production
ES cells
Mice/Embryos
Database
Web server
Data
Mouse Phenotyping Center(s)
KOMP ES cells
EuCOMM ES cells
Microinjection
Germline Transmission
LacZ staining
Lethality/Fertility
Cryopreservation
Tracking
Analysis
Display
Nominate a gene for phenotyping at
Learn about the international effort at
KOMP2 Phenotyping Process
For more information:

14. IDG: Understanding the properties and functions of poorly characterized proteins from 4 protein families that are the most common drug targets
G-Protein Coupled Receptors
Nuclear Receptors
Ion Channels
Protein Kinases
Knowledge Management Center: What do we know, and what do we need to know about members of these protein families?

15. CF Programs Build “Foundations” to Catalyze Research
■ New Approaches to Foster Innovation and Invigorate the Research Workforce
■ High-Risk High-Reward (Pioneer, New Innovator, Transformative Research, Early Independence Awards)
■ Broadening Experiences in Scientific Training (BEST) Awards (New in FY13)
■ Increasing Diversity in the NIH-funded Workforce (New in FY13)
■ New Tools, Infrastructure, and Data to Support or Establish New Fields of Study
■ Extracellular RNA Communication
■ Epigenomics
■ Knock-Out Mouse Phenotyping Project (KOMP2)
■ New Technologies and Approaches to Overcome Barriers to Progress in a Field
■ Structural Biology
■ PROMIS: Patient Report Outcomes Management System
■ Microphysiological Systems for Drug Screening

16. Regulatory Science: Improving the process for developing new therapies
Human-on-a-Chip – a collaborative initiative between NIH, DARPA, and FDA for improved toxicity and efficacy testing
Ten microphysiological systems to be represented on an integrated platform
Must replicate known responses to drugs and toxins
Must allow sustained analysis – up to 4 weeks – with multiple read-outs
Should be extendable to include mimics of pathology
NIH to encourage development of more accurate representations of physiology and pathology
NIH will also encourage development of microsystems from iPS cells

18. For more information: http://commonfund.nih.gov/ 18
Contact information:
Today’s talk – Betsy Wilder
Pioneer, TR01, New Innovators, Early Independence Award – Ravi Basavappa
Other Questions:
Ellie Murcia 18

19. Thank you!
Any Questions?